scholarly journals One year survival of ambulatory patients with the end-stage heart failure: the analysis of prognostic factors

2017 ◽  
Author(s):  
Bożena Szygula-Jurkiewicz ◽  
Wioletta Szczurek ◽  
Michał Skrzypek ◽  
Michał Zakliczyński ◽  
Łukasz Siedlecki ◽  
...  
Keyword(s):  
Heart Failure ◽  
Prognostic Factors ◽  
Ambulatory Patients ◽  
End Stage Heart Failure ◽  
One Year ◽  
End Stage

Biomarkers associated with poor prognosis in patients with end-stage heart failure

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
W Szczurek ◽  
M Gasior ◽  
M Skrzypek ◽  
E Romuk ◽  
B Szygula Jurkiewicz
Keyword(s):  
Heart Failure ◽  
Poor Prognosis ◽  
Funding Source ◽  
Elisa Kit ◽  
Risk Of Death ◽  
End Stage Heart Failure ◽  
One Year ◽  
End Stage ◽  
Medical University

Abstract Background Despite advances in the treatment, end-stage heart failure (HF) is a disease with a severe prognosis, showing an annual mortality rate of 30 to 50%. Due to a poor prognosis in this population of patients, it is necessary to accurately stratify the risk of death, including simple and effective prognostic markers. Objective This study aimed to determine biomarkers associated with mortality in patients with end-stage HF. Material and methods The study was a prospective analysis of optimally treated patients with end-stage HF, who were hospitalised at the Cardiology Department between 2016 and 2018. At the time of enrollment to the study routine laboratory tests, cardiopulmonary exercise tests, echocardiography and right heart catheterization were performed in all patients. Human Interleukin 33 (IL-33) and IL-1 Receptor Like 1 (IL1RL1) were measured by sandwich enzyme-linked immunosorbent assay (ELISA) with the commercially available kit (Human Il-33 and IL1RL1 ELISA kit, SunRedBio Technology Co, Ltd, Shanghai, China). Plasma concentration of N-terminal brain natriuretic peptide (NT-proBNP) was measured using a commercially available kit (Human NTproBNP ELISA kit, Roche Diagnostics, Mannheim, Germany). The endpoint was all-cause mortality during a one-year follow-up. The Medical University of Silesia's local Institutional Review Board approved the study protocol, and all patients provided informed consent. Results The final study group consisted of 282 patients (87.6% males, median age 57.0 years). One-year mortality rate in the analysed population was 28%. In a multivariate analysis, independent risk factors of death included NT-proBNP [Hazard Ratio (HR) 1.056 (95% Confidence Interval (CI): 1.024–1.089); P<0.001], sodium [HR 0.877 (95% CI: 0.815–0.944); p<0.001], IL33 [HR 0.977 (95% CI: 0.965- 0.989); p<0.001] and IL1RL1 [HR 1.015 (95% CI: 1.008–1.023); p<0.001) serum levels. Conclusions Our study showed that lower sodium and IL-33 levels, as well as higher NT-proBNP and IL1RL1 levels are associated with an increased risk of death in patients with end-stage HF during a one-year follow-up. Funding Acknowledgement Type of funding source: Public Institution(s). Main funding source(s): Medical University of SIlesia, Katowice, Poland

scholarly journals SUSTAINED BENEFIT AT ONE YEAR FOLLOW-UP FROM TRANSAPICAL LEFT VENTRICULAR ENDOCARDIAL PACING FOR END STAGE HEART FAILURE

2010 ◽  
Vol 55 (10) ◽  
pp. A16.E155 ◽  
Author(s):  
Attila Mihalcz ◽  
Imre Kassai ◽  
Csaba Foldesi ◽  
Attila Kardos ◽  
Tamas Szili-Torok
Keyword(s):  
Heart Failure ◽  
Left Ventricular ◽  
End Stage Heart Failure ◽  
One Year ◽  
End Stage ◽  
Endocardial Pacing

scholarly journals Outcome Predictors and Safety of Home Dobutamine Intravenous Infusion in End Stage Heart Failure Patients

2021 ◽  
Vol 10 (12) ◽  
pp. 2571
Author(s):  
Antoine Jobbé-Duval ◽  
Thomas Bochaton ◽  
Guillaume Baudry ◽  
Eric Bonnefoy-Cudraz ◽  
Elisabeth Hugon-Vallet ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiogenic Shock ◽  
Multivariate Logistic Regression Analysis ◽  
Surgical Strategies ◽  
Significant Survival ◽  
Tertiary Center ◽  
End Stage Heart Failure ◽  
One Year ◽  
End Stage ◽  
At Home

Patients in end-stage heart failure can experiment cardiogenic shock and may not be weanable from dobutamine. The fate of these patients is a challenge for doctors, patients, family, and the institution. Dobutamine use at home can be a solution. The aim of the present study was to assess the outcome, biological predictors, and safety of dobutamine use at home in dobutamine-dependent patients. All consecutive dobutamine-dependent patients discharged with continuous home intravenous dobutamine, from a single tertiary center between February 2014 and November 2019, were retrospectively analyzed. A total of 19 patients (age 65 ± 10 years) were followed for one year. At one-year, the survival rate was 32%, (6/19). Five (26%) patients had an adverse event related to the intravenous catheter. In a multivariate logistic regression analysis, the combination of a glomerular filtration rate >60 mL/min and a brain natriuretic peptide level <1000 ng/L, were highly predictive of one-year survival (HR = 10.87, IC95% (5.78–36.44), p < 0.001). Management of dobutamine-unweanable patients after cardiogenic shock may involve dobutamine at home to permit a home return. This strategy allows a significant survival and few readmissions, and, if eligible, access to surgical strategies, such as heart transplantation. Simple biological markers at discharge can identify severe patients to refer to palliative care and good responders.

scholarly journals Apelin Improves Prognostic Value of HFSS (Heart Failure Survival Score) and MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) Scales in Ambulatory Patients with End-Stage Heart Failure

2020 ◽  
Vol 9 (7) ◽  
pp. 2300
Author(s):  
Wioletta Szczurek ◽  
Mariusz Gąsior ◽  
Michał Skrzypek ◽  
Bożena Szyguła-Jurkiewicz
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Predictive Power ◽  
Predictive Accuracy ◽  
Meta Analysis ◽  
Survival Score ◽  
Ambulatory Patients ◽  
One Year ◽  
The One ◽  
End Stage

This prospective study aimed to determine the effect of adding apelin to the MAGGIC (Meta-Analysis Global Group In Chronic Heart Failure) and HFSS (Heart Failure Survival Score) scales for predicting one-year mortality in 240 ambulatory patients accepted for heart transplantation (HT) between 2015–2017. The study also investigated whether the combination of N-terminal pro-brain natriuretic peptide (NT-proBNP) with MAGGIC or HFSS improves the ability of these scales to effectively separate one-year survivors from non-survivors on the HT waiting list. The median age of the patients was 58.0 (51.50.0–64.0) years and 212 (88.3%) of them were male. Within a one year follow-up, 75 (31.2%) patients died. The area under the curves (AUC) for baseline parameters was as follows—0.7350 for HFSS, 0.7230 for MAGGIC, 0.7992 for apelin and 0.7028 for NT-proBNP. The HFSS-apelin score generated excellent power to predict the one-year survival, with the AUC of 0.8633 and a high sensitivity and specificity (80% and 78%, respectively). The predictive accuracy of MAGGIC-apelin score was also excellent (AUC: 0.8523, sensitivity of 75%, specificity of 79%). The addition of NT-proBNP to the HFSS model slightly improved the predictive power of this scale (AUCHFFSS-NT-proBNP: 0.7665, sensitivity 83%, specificity 60%), while it did not affect the prognostic strength of MAGGIC (AUCMAGGIC-NT-proBNP: 0.738, sensitivity 71%, specificity 69%). In conclusion, the addition of apelin to the HFSS and MAGGIC models significantly improved their ability to predict the one-year survival in patients with advanced HF. The MAGGIC-apelin and HFSS-apelin scores provide simple and powerful methods for risk stratification in end-stage HF patients. NT-proBNP slightly improved the prognostic power of HFSS, while it did not affect the predictive power of MAGGIC.

Sign in / Sign up

Export Citation Format

Share Document